Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0165-1562 + Semaglutide in Overweight or Obesity
NCT03574584Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2018
- Primary completion
- Jul 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing NNC0165-1562 + Semaglutide with Placebo + Semaglutide (2 arms). Primary endpoint: Number of treatment emergent adverse events. Started Jun 2018; status: completed.
02
Drugs
NNC0165-1562
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT03574584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03574584.